<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0864-084X</journal-id>
<journal-title><![CDATA[Nucleus]]></journal-title>
<abbrev-journal-title><![CDATA[Nucleus]]></abbrev-journal-title>
<issn>0864-084X</issn>
<publisher>
<publisher-name><![CDATA[CUBAENERGIA]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0864-084X2020000100014</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[25 años de CENTIS. Pandemia y Radiofármacos]]></article-title>
<article-title xml:lang="en"><![CDATA[25 years of CENTIS. Pandemic and Radiopharmaceuticals]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cruz Arencibia]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Leyva Montaña]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Morín Zorrilla]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro de Isótopos (CENTIS)  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2020</year>
</pub-date>
<numero>67</numero>
<fpage>14</fpage>
<lpage>21</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0864-084X2020000100014&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0864-084X2020000100014&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0864-084X2020000100014&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen Próximo a su 25 aniversario CENTIS reflexiona sobre su quehacer en el contexto de los trastornos que causa la COVID-19. Con ese propósito se examinan el estado de la medicina nuclear y la radiofarmacia antes y durante la epidemia y sus perspectivas de desarrollo. La producción global de radiofármacos continúa siendo una industria consolidada y aunque la pandemia afecta a esta esfera, la presencia de otras enfermedades no cesa, por lo que los servicios de medicina nuclear esenciales y críticos siguen siendo necesarios. Se espera su paulatina reapertura y que se retome con más fuerza la investigación, dado que la COVID-19 es tan compleja y se asocia a tantos factores que constituye, en perspectiva, terreno virgen para las técnicas diagnósticas en medicina nuclear. Ha de permanecer asimismo el papel de los radiofármacos terapéuticos en un grupo importante de enfermedades, en cáncer sobre todo. El Centro de Isótopos pone por ello énfasis tanto en la consolidación, bajo buenas prácticas, de la producción y el suministro de radiofármacos, como en el desarrollo de nuevos productos. Ambos aspectos se basan principalmente en dos radionúclidos: Tc-99m e Y-90.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Close to its 25th anniversary, CENTIS evaluates its work in the context of the disorders triggered by COVID-19. For this purpose, the situation of nuclear medicine and radiopharmacy, before and during the epidemic and their current development prospects is examined. The production of radiopharmaceuticals continues to be a consolidated global industry and although the pandemic affects this area, the presence of other diseases does not cease, so essential and critical nuclear medicine services are still needed, therefore its gradual reopening is expected. In addition, research will be taken with more strength, given that COVID-19 is so complex and associated with so many factors that it constitutes virgin terrain in perspective for diagnostic techniques in nuclear medicine. The role of therapeutic radiopharmaceuticals in an important set of diseases, especially cancer, will also remain. As a result, the Isotope Center focus its attention under good management practices, on the consolidation of the production and distribution of radiopharmaceuticals and in the development of new products. Both aspects are mainly based on two radionuclides: Tc-99m and Y-90.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[radiofármacos]]></kwd>
<kwd lng="es"><![CDATA[radisótopos]]></kwd>
<kwd lng="es"><![CDATA[tecnecio 99]]></kwd>
<kwd lng="es"><![CDATA[itrio 90]]></kwd>
<kwd lng="es"><![CDATA[coronavirus]]></kwd>
<kwd lng="es"><![CDATA[usos terapéuticos]]></kwd>
<kwd lng="es"><![CDATA[producción de isotopos]]></kwd>
<kwd lng="en"><![CDATA[radiopharmaceuticals]]></kwd>
<kwd lng="en"><![CDATA[radioisotopes]]></kwd>
<kwd lng="en"><![CDATA[technetium 99]]></kwd>
<kwd lng="en"><![CDATA[yttrium 90]]></kwd>
<kwd lng="en"><![CDATA[coronaviruses]]></kwd>
<kwd lng="en"><![CDATA[therapeutic uses]]></kwd>
<kwd lng="en"><![CDATA[isotope production]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>[1]</label><nlm-citation citation-type="">
<source><![CDATA[Nuclear Medicine/Radiopharmaceuticals Market. Nuclear medicine/radiopharmaceuticals market by type (Diagnostic (SPECT - Technetium, PET- F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90)), Application (Oncology, Cardiology) - Global Forecast to 2024]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B2">
<label>[2]</label><nlm-citation citation-type="">
<collab>Radiopharmaceuticals Market</collab>
<source><![CDATA[2019 analysis and review of radiopharmaceuticals market by application - oncology, cardiology, gastroenterology, neuroendocrinology, neurology, and nephrology for 2019 - 2029]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B3">
<label>[3]</label><nlm-citation citation-type="">
<source><![CDATA[Global Radiopharmaceuticals Market - Industry Trends - Forecast to 2026]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B4">
<label>[4]</label><nlm-citation citation-type="confpro">
<collab>National Academies of Sciences, Engineering, and Medicine</collab>
<source><![CDATA[Opportunities and approaches for supplying molybdenum-99 and associated medical isotopes to global markets]]></source>
<year>2018</year>
<conf-name><![CDATA[ Proceedings of a Symposium]]></conf-name>
<conf-loc>DC, Washington </conf-loc>
</nlm-citation>
</ref>
<ref id="B5">
<label>[5]</label><nlm-citation citation-type="">
<collab>OPS/OMS</collab>
<source><![CDATA[Repositorio Institucional para el Intercambio de Información (IRIS). Indicadores básicos 2019. Tendencias de salud en Las Américas]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B6">
<label>[6]</label><nlm-citation citation-type="">
<source><![CDATA[Market Data Forecast. Latin America nuclear medicine radiopharmaceuticals market research report - segmented by diagnostics, by therapeutics, by application, by country (Mexico, Brazil, Argentina, Chile and Rest of Latin America) - Industry Analysis, Size, Share, Growth, Trends, Forecasts (2019-2024)]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B7">
<label>[7]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[PÁEZ]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[ORELLANA]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[GUTIÉRREZ]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[RAMIREZ]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[MUT]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[TORRES]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current status of nuclear medicine practice in latin america and the caribbean]]></article-title>
<source><![CDATA[J Nucl Med]]></source>
<year>2015</year>
<volume>56</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1629-34</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>[8]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[HENNRICH]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[KOPKA]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lutathera®: The First FDA- and EMA-Approved radiopharmaceutical for peptide receptor radionuclide therapy]]></article-title>
<source><![CDATA[pharmaceuticals (Basel)]]></source>
<year>2019</year>
<volume>12</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>114</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>[9]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[SCHWARZ]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[CLARKE]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Perspective on how the fda should review diagnostic radiopharmaceuticals]]></article-title>
<source><![CDATA[J Nucl Med]]></source>
<year>2018</year>
<volume>59</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>865-7</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>[10]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[SCHWARZ]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[DECRISTOFORO]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Harmonization of U.S., European Union, and Canadian first-in-human regulatory requirements for radiopharmaceuticals: is this possible?]]></article-title>
<source><![CDATA[J Nucl Med]]></source>
<year>2019</year>
<volume>60</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>158-66</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>[11]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[SCHWARZ]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[DECRISTOFORO]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[US and EU radiopharmaceutical diagnostic and therapeutic nonclinical study requirements for clinical trials authorizations and marketing authorizations]]></article-title>
<source><![CDATA[EJNMMI Radiopharmacy and Chemistry]]></source>
<year>2019</year>
<volume>4</volume>
<page-range>10</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>[12]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[SHARMA]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[KAUR]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[SHARMA]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radiopharmaceuticals regulations: current scenario and the way forward]]></article-title>
<source><![CDATA[Applied Clinical Research, Clinical Trials &amp; Regulatory Affairs]]></source>
<year>2017</year>
<volume>4</volume>
<page-range>1-12</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>[13]</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[DECRISTOFORO]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[LYASHCHENKO]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recommendations for conducting clinical trials with radiopharmaceuticals]]></article-title>
<source><![CDATA[nuclear medicine textbook]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B14">
<label>[14]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[NEELS]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[PATT]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[DECRISTOFORO]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radionuclides: medicinal products or rather starting materials?]]></article-title>
<source><![CDATA[EJNMMI Radiopharmacy and Chemistry]]></source>
<year>2019</year>
<volume>4</volume>
<page-range>22</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>[15]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[SHARMA]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[SANYOG]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intricacies in the approval of radiopharmaceuticals - regulatory perspectives and the way forward]]></article-title>
<source><![CDATA[Current Science]]></source>
<year>2019</year>
<volume>116</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>47-65</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>[16]</label><nlm-citation citation-type="">
<collab>U.S. Department of Health and Human Services. Food and Drug Administration</collab>
<source><![CDATA[Center for Drug Evaluation and Research (CDER). Oncology therapeutic radiopharmaceuticals: nonclinical studies and labeling recommendations guidance for industry (pharmacology/toxicology)]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B17">
<label>[17]</label><nlm-citation citation-type="">
<collab>Food and Drug Administration (FDA)</collab>
<source><![CDATA[E17 General principles for planning and design of multiregional clinical trials. FDA, 2018]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B18">
<label>[18]</label><nlm-citation citation-type="">
<source><![CDATA[AuntMinnie.com]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B19">
<label>[19]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MERKEL]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[WHICHER]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[BOMANJI]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[HERRMANN3]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Realising the potential of radioligand therapy: policy solutions for the barriers to implementation across Europe]]></article-title>
<source><![CDATA[European Journal of Nuclear Medicine and Molecular Imaging]]></source>
<year>2020</year>
<volume>47</volume>
<page-range>1335-9</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>[20]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[PAEZ]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[GNANASEGARAN]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[FANTI]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[COVID-19 pandemic: guidance for nuclear medicine departments]]></article-title>
<source><![CDATA[Eur J Nucl Med Mol Imaging]]></source>
<year>2020</year>
<volume>47</volume>
<page-range>1615-9</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>[21]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[HUANG]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
<name>
<surname><![CDATA[GNANASEGARAN]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[PAEZ]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nuclear medicine services after COVID-19: gearing up back to normality]]></article-title>
<source><![CDATA[Eur J Nucl Med Mol Imaging]]></source>
<year>2020</year>
<volume>47</volume>
<page-range>2048-53</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>[22]</label><nlm-citation citation-type="book">
<collab>International Atomic Energy Agency (IAEA)</collab>
<source><![CDATA[COVID-19 pandemic: technical guidance for nuclear medicine departments]]></source>
<year>2020</year>
<page-range>50</page-range><publisher-loc><![CDATA[Vienna ]]></publisher-loc>
<publisher-name><![CDATA[IAEA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B23">
<label>[23]</label><nlm-citation citation-type="">
<collab>Human Health Campus</collab>
<source><![CDATA[https://humanhealth.iaea.org/HHW/ Global Radiopharmaceuticals Market (COVID 19 UPDATE) Overview by Type, Technological Advancements &amp; Forecast to 2027]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B24">
<label>[24]</label><nlm-citation citation-type="">
<source><![CDATA[Radiopharmaceuticals Market Analysis 2020- Industry Trend, Revenue, Top Players, Size, Share, COVID-19 Impact, Region, Feasibility, Economics, Pricing Analysis, Opportunities, Forecast to 2025]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B25">
<label>[25]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[BOSCHI]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[LICIA UCCELLI]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[MARTINI]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A picture of modern Tc-99m radiopharmaceuticals: production, chemistry, and applications in molecular imaging]]></article-title>
<source><![CDATA[Review. Appl. Sci]]></source>
<year>2019</year>
<volume>9</volume>
<page-range>2526-42</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>[26]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[PILLAI]]></surname>
<given-names><![CDATA[MRA]]></given-names>
</name>
<name>
<surname><![CDATA[NANABALA]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[JOY]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[SASIKUMAR]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[KNAPP]]></surname>
<given-names><![CDATA[FF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radiolabeled enzyme inhibitors and binding agents targeting psma: effective theranostic tools for imaging and therapy of prostate cancer]]></article-title>
<source><![CDATA[Nucl Med Biol]]></source>
<year>2016</year>
<volume>43</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>692-720</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>[27]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[LEE]]></surname>
<given-names><![CDATA[WW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical applications of technetium-99m quantitative single-photon emission computed tomography/computed tomography]]></article-title>
<source><![CDATA[Nucl Med Mol Imaging]]></source>
<year>2019</year>
<volume>53</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>172-81</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>[28]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MANTEL]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[WILLIAMS]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An introduction to newer PET diagnostic agents and related therapeutic radiopharmaceuticals]]></article-title>
<source><![CDATA[J of Nucl. Med. and Technol]]></source>
<year>2019</year>
<volume>47</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>203-9</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>[29]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[SWACHCHHANDA]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[PANKAJ]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Axumin positron emission tomography: novel agent for prostate cancer biochemical recurrence]]></article-title>
<source><![CDATA[J Clin Imaging Sci]]></source>
<year>2019</year>
<volume>9</volume>
<numero>49</numero>
<issue>49</issue>
</nlm-citation>
</ref>
<ref id="B30">
<label>[30]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[PETRONI]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[MENICHETTI]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[POLI]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Historical and radiopharmaceutical relevance of [18F] FDG]]></article-title>
<source><![CDATA[Journal of Radioanalytical and Nuclear Chemistry]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B31">
<label>[31]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[SOLNES]]></surname>
<given-names><![CDATA[LB]]></given-names>
</name>
<name>
<surname><![CDATA[WERNER]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
<name>
<surname><![CDATA[JONES]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[SADAGHIANI]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Theranostics: leveraging molecular imaging and therapy to impact patient management and secure the future of nuclear medicine]]></article-title>
<source><![CDATA[J. of Nucl. Med]]></source>
<year>2020</year>
<volume>61</volume>
<page-range>311-8</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>[32]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[KENDI]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[HALFDANARSON]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
<name>
<surname><![CDATA[PACKARD]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[DUNDAR]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[SUBRAMANIAM]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Therapy With 177Lu-DOTATATE: clinical implementation and impact on care of patients with neuroendocrine tumors]]></article-title>
<source><![CDATA[Review. Nucl. Med. and Mol. Imaging]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B33">
<label>[33]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ALBERTI RAMÍREZ]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[GARCÍA RODRÍGUEZ]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[CRUZ ARENCIBIA]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[MORÍN ZORRILLA]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fósforo-32 e Itrio-90 como opciones en el tratamiento del dolor óseo metastásico]]></article-title>
<source><![CDATA[Nucleus]]></source>
<year>2016</year>
<numero>60</numero>
<issue>60</issue>
<page-range>24-8</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>[34]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[SOWA-STASZCZAK]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of 90Y-DOTATATE, therapy in neuroendocrine tumours]]></article-title>
<source><![CDATA[Polish Journal of Endocrinology]]></source>
<year>2011</year>
<volume>62</volume>
<page-range>5</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>[35]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[CWIKLA]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study]]></article-title>
<source><![CDATA[Annals of Oncology]]></source>
<year>2010</year>
<volume>21</volume>
<page-range>787-94</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>[34]</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[SCHULTZ]]></surname>
<given-names><![CDATA[WA]]></given-names>
</name>
</person-group>
<source><![CDATA[Molecular Biology of Human Cancers]]></source>
<year>2005</year>
<publisher-name><![CDATA[Springer Science + Business Media, Inc.]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B37">
<label>[36]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[HICKS]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[JACKSON]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[KONG]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[WARE]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[64Cu-SARTATE PET Imaging of patients with neuroendocrine tumors demonstrates high tumor uptake and retention, potentially allowing prospective dosimetry for peptide receptor radionuclide therapy]]></article-title>
<source><![CDATA[J Nucl Med]]></source>
<year>2019</year>
<volume>60</volume>
<page-range>777-85</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>[37]</label><nlm-citation citation-type="">
<collab>ClinicalTrials.gov</collab>
<source><![CDATA[Identifier: NCT04023331. 67Cu-SARTATE&#8482; peptide receptor radionuclide therapy administered to pediatric patients with high-risk neuroblastoma]]></source>
<year></year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
